FREMONT, Calif. and
CAMBRIDGE, England, Jan. 4, 2022
/PRNewswire/ -- Alamar Biosciences (Alamar), a platform
company focused on transforming the field of proteomics to enable
the early detection of cancer and other diseases, and Abcam
(AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences
research tools, today announced a strategic partnership to further
understanding of the human proteome.
The field of proteomic analysis is in the spotlight. Its
advance not only enhances the understanding of fundamental biology,
but also sheds light on the status of human health and disease. A
deeper understanding of the proteome is set to play a crucial role
in enabling the next wave of innovations in research, diagnostics
and therapeutics. Powering this effort requires new technology
platforms that are able to address the two essential goals in
proteomic analysis, namely the ability to go as deeply as possible
to detect very low abundance proteins and the ability to profile
thousands of proteins in a single sample.
Dr. Yuling Luo, Founder &
CEO of Alamar, commented: "Alamar is working to enable the
early detection of cancer and other diseases by simultaneous
measurement of hundreds to thousands of targets, even those present
in minute amounts. We are very happy to partner with Abcam to
access their extensive portfolio of recombinant monoclonal antibody
pairs, which will accelerate our ability to bring our proteomic
discovery tools to researchers."
"We are excited to be partnering with Alamar as they
develop an automated proteomics platform that has the potential to
offer unprecedented combination of sensitivity, plex-level and
dynamic range," commented Dr Emma Sceats, SVP Sales, Service and Business
Development at Abcam. "The NULISA technology
platform will provide an important tool for life science
research, pharmaceutical development and diagnostics, enhancing
understanding of the circulating proteome and supporting low
abundance biomarker discovery. Such capability will be
critical for the discovery and measurement of many proteins in
human plasma and other samples that are currently
undetectable."
Abcam's portfolio of over 1,300 fit-for-purpose recombinant
antibody pairs is actively curated to ensure that it is
representative of the key disease areas of interest. Designed to
enhance biomarker discovery and support deeper understanding of the
circulating proteome, the portfolio has been pre-validated
specifically for multiplex applications.
About Alamar Biosciences
Alamar Biosciences is a privately held life sciences company
with a mission to transform the field of proteomics to enable the
early detection of cancer and other diseases. The company's two
proprietary technology platforms, NULISA™ and Attobody™, work
seamlessly with the latest advances in genomics to achieve
single-digit attomolar detection sensitivity, greatly surpassing
the most sensitive protein detection technology on the market
today. The Attobodies have picomolar affinity and built-in high
specificity and have the potential to expand antibody therapeutics
to many targets intractable with conventional antibodies. For more
information, please visit www.alamarbio.com.
About Abcam plc
As a global life sciences company, Abcam identifies, develops,
and distributes high-quality biological reagents and tools that are
crucial to research, drug discovery and diagnostics. Working across
the industry, the Company supports life scientists to achieve their
mission, faster.
Abcam partners with life sciences organizations to co-create
novel binders for use in drug discovery, in vitro
diagnostics and therapeutics, driven by the Company's proprietary
discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays, Abcam is
helping advance the global understanding of biology and causes of
disease, which enables new treatments and improved health. The
Company's pioneering data-sharing approach gives scientists
increased confidence in their results by providing validation, user
comments and peer-reviewed citations for its 90,000 products.
With 14 sites globally, many of Abcam's over 1,600-strong team
are located in the world's leading life sciences research hubs,
complementing a global network of service and support.
To find out more, please
visit www.abcam.com and corporate.abcam.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alamar-biosciences-partners-with-abcam-to-drive-understanding-of-the-human-proteome-301447478.html
SOURCE Abcam; Alamar Biosciences